US priority review status for oral MS drug Cladribine
US priority review status for oral MS drug Cladribine
German pharmaceutical and chemicals company Merck KGaA has announced that the U.S. Food and Drug Administration accepted a new drug application for its oral multiple sclerosis treatment Cladribine with a priority review designation, after Merck's initial submission was rejected last fall.
Priority review status is applied to drugs that have the potential to provide significant advances in treatment and means the FDA will complete its review in six months rather than the usual 10. Merck expects a decision in the fourth quarter....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1686 Views
-
Last post by jimmylegs
-
- 3 Replies
- 1538 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1883 Views
-
Last post by frodo
-
- 0 Replies
- 1680 Views
-
Last post by frodo
-
- 0 Replies
- 2021 Views
-
Last post by NHE
-
- 0 Replies
- 1231 Views
-
Last post by NHE
-
- 1 Replies
- 1723 Views
-
Last post by frodo
-
- 0 Replies
- 1226 Views
-
Last post by frodo
-
- 0 Replies
- 1785 Views
-
Last post by frodo